📈 Ticker:
ABT (Abbott Laboratories)
🕒 Timeframe: Daily
💡 Strategy: Ichimoku + MACD + Risk/Reward Setup
Abbott (
ABT) is showing a compelling long opportunity after a pullback to the Tenkan-sen (conversion line) within the Ichimoku Cloud structure. Price action remains bullish as it respects the cloud, and the MACD just crossed bullish recently—momentum is still positive despite today’s dip.
🔍 Key Levels
Entry: ~$131.53
Stop: ~$128.20 (below the cloud base & local support)
Target: ~$144.66 (previous R1 pivot zone)
R:R = 3.92
💬 Why This Trade?
Price is supported by the cloud and hasn’t broken structure
Strong MACD momentum despite minor consolidation
Healthy pullback offers a low-risk re-entry point
ABT is fundamentally strong with consistent EPS growth and global demand across diagnostics and nutrition
🧠 Bonus: ABT's diversified healthcare portfolio provides a defensive edge, especially during macro uncertainty. Upcoming earnings could be a potential catalyst.
🕒 Timeframe: Daily
💡 Strategy: Ichimoku + MACD + Risk/Reward Setup
Abbott (
🔍 Key Levels
Entry: ~$131.53
Stop: ~$128.20 (below the cloud base & local support)
Target: ~$144.66 (previous R1 pivot zone)
R:R = 3.92
💬 Why This Trade?
Price is supported by the cloud and hasn’t broken structure
Strong MACD momentum despite minor consolidation
Healthy pullback offers a low-risk re-entry point
ABT is fundamentally strong with consistent EPS growth and global demand across diagnostics and nutrition
🧠 Bonus: ABT's diversified healthcare portfolio provides a defensive edge, especially during macro uncertainty. Upcoming earnings could be a potential catalyst.
Trade closed manually
Still think that has potential but not moving fast enough for me. Closing this one out and focusing on better trades. Note
4.6% gain. Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.